Abbott Laboratories $ABT Shares Bought by MGO One Seven LLC

MGO One Seven LLC lifted its stake in Abbott Laboratories (NYSE:ABT) by 19.3% during the second quarter, Holdings Channel reports. The institutional investor owned 25,403 shares of the healthcare product maker’s stock after acquiring an additional 4,109 shares during the quarter. MGO One Seven LLC’s holdings in Abbott Laboratories were worth $3,455,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of ABT. Hughes Financial Services LLC acquired a new position in shares of Abbott Laboratories in the 1st quarter valued at $27,000. Abound Financial LLC purchased a new position in Abbott Laboratories in the first quarter valued at $28,000. Elequin Capital LP acquired a new position in shares of Abbott Laboratories in the first quarter worth about $30,000. JCIC Asset Management Inc. purchased a new stake in shares of Abbott Laboratories during the 1st quarter worth about $32,000. Finally, Vision Financial Markets LLC purchased a new position in shares of Abbott Laboratories in the 1st quarter valued at about $33,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ABT has been the topic of a number of recent analyst reports. Benchmark assumed coverage on Abbott Laboratories in a research report on Friday. They set a “buy” rating and a $145.00 price target on the stock. Raymond James Financial dropped their price target on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a research note on Friday, July 18th. Weiss Ratings reissued a “buy (b)” rating on shares of Abbott Laboratories in a report on Wednesday, October 8th. Leerink Partnrs raised shares of Abbott Laboratories to a “hold” rating in a report on Monday, June 16th. Finally, Wells Fargo & Company reduced their price target on shares of Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a research report on Friday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $146.17.

Abbott Laboratories Stock Down 0.8%

ABT stock opened at $131.52 on Tuesday. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The firm has a 50-day moving average of $132.57 and a two-hundred day moving average of $131.60. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The company has a market cap of $228.90 billion, a price-to-earnings ratio of 16.48, a PEG ratio of 2.51 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. During the same period in the prior year, the business earned $1.14 earnings per share. The business’s revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be issued a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s payout ratio is currently 29.57%.

Insider Buying and Selling at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.